[1][2][3] The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science.
The current (March 2022) Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.
[17] Structures that constitute complexes with synthetic small molecules is aided by a partnership with the Diamond synchrotron in Oxfordshire.
[18] The chemical probe program prioritizes (members of) protein families that are relatively understudied, or which may be currently relevant to human biology and drug discovery.
The chemical probes conform to the now community-standard quality criteria created by the SGC and its collaborative network.
[10][34][35][36][37][38] The Structure-guided Drug Discovery Coalition (SDDC) comprises the Seattle Structural Genomics Center for Infectious Disease (SSGCID), the Midwest Center for Structural Genomics, the Center for Structural Genomics of Infectious Diseases (CSGID), and drug discovery teams from academia and industry has resulted in 7 early drug leads for tuberculosis (TB), malaria, and cryptosporidiosis.
The M4 companies are wholly owned by a Canadian charity Agora Open Science Trust whose mandate is to share scientific knowledge and ensure affordable access to all medicines.
M4K Pharma has the most advanced open drug discovery program[14] and is supported with funding from the Ontario Institute for Cancer Research, The Brain Tumour Charity, Charles River Laboratories and Reaction Biology, and with contributions from scientists at the Universities of McGill, North Carolina, Oxford, Pennsylvania, and Toronto and in the Sant Joan de Déu hospital, the University Health Network hospitals, the Hospital for Sick Children, and The Institute for Cancer Research.
The SGC scientific program was launched, with activities at the Universities of Oxford and Toronto, and with a mandate to contribute >350 human protein structures into the public domain.
Experimental activities started at the Karolinska Institutet in Stockholm, led by Pär Nordlund and Johan Weigelt.
With support from Wellcome and GSK, the SGC launched a program to develop freely-available chemical probes to proteins involved in epigenetic signalling which at the time were under studied.
The SGC initiated a concerted effort to develop disease-relevant, cell-based assays using (primary) cells or tissue from patients.
[citation needed] Target 2035 is an open science movement with the goal of creating chemical[12][24][29][32][33] and/or biological[13][59] tools for the entire proteome by 2035.
Supporting projects currently underway include the SGC’s epigenetics chemical probe program,[62][63][64] the NIH’s Illuminating the Druggable Genome initiative for under-explored kinases, GPCR’s and ion channels,[65][66][67] IMI’s RESOLUTE project on human SLCs,[22] and IMI's Enabling and Unlocking Biology in the Open (EUbOPEN).